Scholarlink

Purpose <p>Designer benzodiazepines (D-BZDs) are a subclass of new psychoactive substances (NPS) posing heightened health risks. Pyrazolam, a triazolobenzodiazepine never marketed for medical use, remains poorly documented in clinical settings. The purpose of this study was to investigate an acute intoxication case to pyrazolam with quantification of this D-BZD in the different collected non biological and biological samples.</p> Methods <p>Toxicological analyses were performed on plasma, urine, gastric aspirate, hair, and the ingested liquid using targeted and untargeted liquid chromatography–high-resolution mass spectrometry (LC-HRMS/MS), gas chromatography with flame ionization detection (GC-FID), and gas chromatography–mass spectrometry (GC-MS). The detectability of pyrazolam using routine immunoassays was also assessed.</p> Results <p>The vodka solution contained ethanol (330&#xa0;g/L) and pyrazolam (450&#xa0;mg/L). Plasma pyrazolam concentration reached 500 ng/mL five hours post-ingestion and decreased to 270 ng/mL at 72&#xa0;h. Pyrazolam, its glucuronide metabolite, and several co-ingested substances such as methylenedioxy-α-pyrrolidinohexaphenone, pentylone, methadone and commercial benzodiazepines were detected in the investigated matrices. Immunoassays allowed the detection of pyrazolam only in urine. Hair analysis supported the recent NPS use.</p> Conclusions <p>This case highlights the risk of severe intoxication with D-BZD and underscores the value of high-resolution mass spectrometry to identify emerging substances which may not be included in targeted approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An unusual way of acute Pyrazolam poisoning in consumer of commercially approved benzodiazepines

  • 期刊论文

  • 发表日期：

    2025年12月8日

查看全文
  • Romain Magny,
  • Arezki Khaled Boukerma,
  • Amine Mihoubi,
  • Laurence Labat,
  • Pascal Houzé

摘要

Purpose

Designer benzodiazepines (D-BZDs) are a subclass of new psychoactive substances (NPS) posing heightened health risks. Pyrazolam, a triazolobenzodiazepine never marketed for medical use, remains poorly documented in clinical settings. The purpose of this study was to investigate an acute intoxication case to pyrazolam with quantification of this D-BZD in the different collected non biological and biological samples.

Methods

Toxicological analyses were performed on plasma, urine, gastric aspirate, hair, and the ingested liquid using targeted and untargeted liquid chromatography–high-resolution mass spectrometry (LC-HRMS/MS), gas chromatography with flame ionization detection (GC-FID), and gas chromatography–mass spectrometry (GC-MS). The detectability of pyrazolam using routine immunoassays was also assessed.

Results

The vodka solution contained ethanol (330 g/L) and pyrazolam (450 mg/L). Plasma pyrazolam concentration reached 500 ng/mL five hours post-ingestion and decreased to 270 ng/mL at 72 h. Pyrazolam, its glucuronide metabolite, and several co-ingested substances such as methylenedioxy-α-pyrrolidinohexaphenone, pentylone, methadone and commercial benzodiazepines were detected in the investigated matrices. Immunoassays allowed the detection of pyrazolam only in urine. Hair analysis supported the recent NPS use.

Conclusions

This case highlights the risk of severe intoxication with D-BZD and underscores the value of high-resolution mass spectrometry to identify emerging substances which may not be included in targeted approaches.